Brain Cancer Trial, Recruiting NCT04111588 Sponsor: Norwegian University of Science and Technology Condition: Brain Cancer
Back to Brain Cancer

Brain Cancer Trial, Recruiting

NCT04111588
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For people with glioma (a type of brain tumour):

  • People who have been diagnosed with or are planned to be treated for a WHO grade II, III, or IV diffuse glioma (a range of brain tumour types, from lower to higher severity)
  • Adults aged 18 years or older
  • People who are planned to have a tissue sample taken to confirm their diagnosis
  • People who are reasonably able to care for themselves day-to-day (confirm with trial site)

For people with brain metastases (cancer that has spread to the brain):

  • People who have between 1 and 4 brain metastases and are being considered for surgery or a targeted radiation treatment called stereotactic radiosurgery
  • People planned for surgery who are either suspected of having brain metastases or already have a confirmed diagnosis
  • People planned for stereotactic radiosurgery who have a known primary cancer (the original cancer in another part of the body)
  • Adults aged 18 years or older
  • People whose doctors estimate they are likely to survive at least 3 months after joining the trial

Who may not be able to join:

  • People who have a pacemaker or defibrillator that is not compatible with a 3 Tesla (3T) MRI scanner
  • People who are unable to give informed consent, for example due to significant difficulties with speech or thinking
  • People who are pregnant (a pregnancy test may be required for women of childbearing age if there is any uncertainty)
  • People who are currently breastfeeding
  • People who weigh more than 120 kg

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Live Eikenes, Phd, Norwegian University of Science and Technology

Phone: 0047 99568081

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Norwegian University of Science and Technology
Registry
ClinicalTrials.gov
Start date
25 November 2019
Est. completion
31 December 2025

Where this trial is recruiting

🇳🇴 Norway

Primary endpoints

Diagnostic accuracy in detecting brain tumor tissue at baseline

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov